Background Among patients with non–small-cell lung cancer (NSCLC), data on intratumor
heterogeneity and cancer genome evolution have been limited to small retrospective cohorts. …

Although cancer chemotherapy has historically been considered immune suppressive, it is
now accepted that certain chemotherapies can augment tumor immunity. The recent success …

Background We evaluated capecitabine (an oral fluoropyrimidine) and oxaliplatin (a platinum
compound) as alternatives to infused fluorouracil and cisplatin, respectively, for untreated …

The early detection of relapse following primary surgery for non-small-cell lung cancer and
the characterization of emerging subclones, which seed metastatic sites, might offer new …

Background We aimed to assess the efficacy and safety of sequential or simultaneous
telomerase vaccination (GV1001) in combination with chemotherapy in patients with locally …

Background The ESPAC-3 trial showed that adjuvant gemcitabine is the standard of care
based on similar survival to and less toxicity than adjuvant 5-fluorouracil/folinic acid in patients …

Background Individuals with cancer, particularly those who are receiving systemic anticancer
treatments, have been postulated to be at increased risk of mortality from COVID-19. This …

The importance of intratumour genetic and functional heterogeneity is increasingly recognised
as a driver of cancer progression and survival outcome. Understanding how tumour …

The majority of targeted therapies for non-small-cell lung cancer (NSCLC) are directed
against oncogenic drivers that are more prevalent in patients with light exposure to tobacco …

Purpose To determine whether adding cetuximab to irinotecan prolongs survival in patients
with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine and …